,
(ii) delayed transformation of morulae to blastocysts (Wu et al, 1971;  Roblero and Garavagno, 1979; Roblero et al, 1987; Vinijsanun et al, 1990; Yang and Wu, 1990; Vinijsanun and Martin, 1991) or (iii) significantly fewer cells per embryo (Roblero, 1973; Roblero and Garavagno, 1979; Roblero et al, 1987 However, immunoneutralization of progesterone using mono¬ clonal antibodies either arrested embryo development or caused only a slight delay in the transformation of morulae to blastocysts, depending upon whether the DB3 monoclonal (Wang et al, 1984) or the 11P27 monoclonal antibody (Vinijsanun et al, 1990) , respectively, was used. Moreover, Heap et al. (1988) reported an inability to confirm their earlier findings (Wang et al, 1984) . Furthermore, the effectiveness of monoclonal antiprogesterone antibodies in blocking pregnancy in mice is strain specific (Rider et al, 1986; Vinijsanun et al, 1990) , and is highly effective only in mice syngeneic to those in which the antibodies are generated, suggesting an immunological, rather than anti-progesterone, mode of action (Vinijsanun et al, 1990) . Conflicting results have also been obtained using the steroid progesterone antag¬ onist RU486 (17ß-hydroxy-llß-(4-dimethylaminophenyl-l)-17a(prop-l-ynyI)-estra-4,9-dien-3-one): several studies have reported either retarded embryo development (Roblero et al, 1987; Yang and Wu, 1990) (Fig. lb) al (1990) reported that RU486 treatment of ovariectomized rats at 10 mg kg~, similar to those used in this study 2.5-10 mg kg-1, was associated with increased synthesis and secretion of adenocorticotrophic hormone, pre¬ sumably because of inhibition of glucocorticoid-induced nega¬ tive feedback. This finding suggests that because of enhanced ACTH secretion, plasma glucocorticoid concentrations were higher in RU486-treated mice, as has been observed in rats (Okada et al, 1988) . There are many glucocorticoid effects, many of which exhibit differing dose-response relationships (Chrousos et al, 1988 
